Pharmion (PHRM) Receives FDA Approval of Vidaza NDA Supplement for IV Administration
Pharmion Corporation (Nasdaq: PHRM) has received approval from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) supplement to add intravenous (IV) use as a new route of administration to the instructions in the approved prescribing information for its DNA demethylating agent Vidaza. With this approval, Vidaza may now be administered intravenously over a period of 10 to 40 minutes in a clinic or hospital setting.
You May Also Be Interested In
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
- Medicis (MRX) Gets Verbal Notice of Allowance for ZYCLARA Patent on Actinic Keratosis
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
